Antifungal prophylaxis with Amphotericin B deoxycholate emulsified in lipids for acute myeloid leukemia patients treated in low economy countries

1Clinical Haematology and Bone Marrow Transplant Unit, Civil Service Hospital, Kathmandu, Nepal, 2Department of Clinical Oncology and Chemotherapy, Nagoya University Hospital, Nagoya, Japan, 3Department of Pharmacology, 4Department of Pathology and Clinical Haematology Unit, Civil Service Hospital, Kathmandu, Nepal, 5Intensive Care Unit, Tribhuwan University Teaching Hospital, Kathmandu, Nepal, and 6 Division of Hematology/Oncology, Department of Medicine, UI Cancer Center and Center for Global Health, University of Illinois at Chicago, Chicago, IL, USA

[1]  J. Perfect,et al.  Update on epidemiology of and preventive strategies for invasive fungal infections in cancer patients. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  S. Sundar,et al.  Efficacy and Safety of Amphotericin B Emulsion versus Liposomal Formulation in Indian Patients with Visceral Leishmaniasis: A Randomized, Open-Label Study , 2014, PLoS neglected tropical diseases.

[3]  D. Kontoyiannis,et al.  Effectiveness of Primary Anti-Aspergillus Prophylaxis during Remission Induction Chemotherapy of Acute Myeloid Leukemia , 2014, Antimicrobial Agents and Chemotherapy.

[4]  A. Chakrabarti,et al.  Invasive aspergillosis in developing countries. , 2011, Medical mycology.

[5]  S. Arya,et al.  Demograhic pattern, clinical features and treatment outcome of patients with infective keratitis in the eastern region of Nepal. , 2009, Nepalese journal of ophthalmology : a biannual peer-reviewed academic journal of the Nepal Ophthalmic Society : NEPJOPH.

[6]  D. DeAngelo,et al.  Invasive fungal disease in patients treated for newly diagnosed acute leukemia , 2010, American journal of hematology.

[7]  L. Pagano,et al.  Current therapeutic approaches to fungal infections in immunocompromised hematological patients. , 2010, Blood reviews.

[8]  Patricia Muñoz,et al.  Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  M. Robin,et al.  Safety of a weekly high dose of liposomal amphotericin B for prophylaxis of invasive fungal infection in immunocompromised patients: PROPHYSOME Study. , 2008, International journal of antimicrobial agents.

[10]  S. Bhandary,et al.  Fungal maxillary sinusitis: a prospective study in a tertiary care hospital of eastern Nepal. , 2007, Kathmandu University medical journal.

[11]  E. Thiel,et al.  Low-dose liposomal amphotericin B in the prevention of invasive fungal infections in patients with prolonged neutropenia: results from a randomized, single-center trial. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  D. Touw,et al.  Amphotericin B colloidal dispersion (Amphocil) vs fluconazole for the prevention of fungal infections in neutropenic patients: data of a prematurely stopped clinical trial , 2000, Bone Marrow Transplantation.

[13]  S. Khan,et al.  A randomized comparison of fluconazole with amphotericin B as empiric anti-fungal agents in cancer patients with prolonged fever and neutropenia. , 1998, The American journal of medicine.

[14]  J. Montoro,et al.  Administration of Lipid-Emulsion Versus Conventional Amphotericin B in Patients with Neutropenia , 1995, The Annals of pharmacotherapy.

[15]  H. Horowitz,et al.  Fluconazole Prophylaxis of Fungal Infections in Patients with Acute Leukemia: Results of a Randomized Placebo-Controlled, Double-Blind, Multicenter Trial , 1993, Annals of Internal Medicine.

[16]  M. Kurusz,et al.  Efficacy and safety , 2021, Perfusion.

[17]  P. Gøtzsche,et al.  Amphotericin B lipid soluble formulations vs amphotericin B in cancer patients with neutropenia. , 2000, The Cochrane database of systematic reviews.

[18]  S. McCann,et al.  Liposomal amphotericin (AmBisome) in the prophylaxis of fungal infections in neutropenic patients: a randomised, double-blind, placebo-controlled study , 1999, Bone Marrow Transplantation.